Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Table 2 Summary of changes in MSTCQ scores from Week 4 to 12 in the intent-to-treat population (n = 119)

Time point	ISR*	FLS*	GSE^†
Week 4 (n = 115)
Mean (SD)	13.2 (4.02)	13.4 (4.56)	6.8 (3.16)
Median (range)	13 (4-19)	13 (6-20)	6 (3-15)
Week 8 (n = 109)
Mean (SD)	13.4 (3.64)	12.9 (4.10)	7.5 (3.16)
Median (range)	13.5 (6-20)	12 (5-20)	8 (3-15)
Week 12 (n = 104)
Mean (SD)	13.1 (3.39)	12.2 (4.30)	7.6 (3.05)
Median (range)	13 (6-20)	11 (5-20)	8 (3-15)
p-value^‡	0.902	0.022	0.002

*Range: 1 (mild) to 20 (severe)
^†Range: 1 (poor treatment satisfaction) to 15 (excellent treatment satisfaction)
^‡Repeated measures analysis of variance
FLS 'flu-like' symptoms, GSE global side effects, ISR injection-site reactions; MSTCQ Multiple Sclerosis Treatment Concern Questionnaire, SD standard deviation